Treating prediabetes with metformin systematic review and meta-analysis

Canadian Family Physician

Volumn 55, Issue 4, 2009, Pages 363-369

  Lilly, Muriel ^a   Godwin, Marshall ^a  

^a Health Sciences Centre St John's   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

METFORMIN;

BEHAVIOR MODIFICATION; CLINICAL TRIAL; DIABETES CONTROL; DIET RESTRICTION; ETHNIC DIFFERENCE; FOLLOW UP; HUMAN; IMPAIRED GLUCOSE TOLERANCE; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; NEWFOUNDLAND AND LABRADOR; PREDIABETIC STATE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 66749190901     PISSN: 0008350X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Wen CP, Cheng TY, Tsai SP, Hsu HL, Wang SL. Increased mortality risks of pre-diabetes (impaired fasting glucose) in Taiwan. Diabetes Care 2005;28(11):2756-61.
2. Unwin N, Shaw J, Zimmet P, Alberti KG. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002;19(9):708-23.
3. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, et al. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta- analysis. BMJ 2007;334(7588):299. Epub 2007 Jan 19.
4. Eguchi K, Tomizawa H, Ishikawa J, Hoshide S, Numao T, Fukuda T, et al. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Hypertens Res 2007;30(1):23-30.
5. Ramachandran A, Snehalatha C, Satyavani K, Sivasankari S, Vijay V. Metabolic syndrome does not increase the risk of conversion of impaired glucose tolerance to diabetes in Asian Indiansresult of Indian Diabetes Prevention Programme. Diabetes Res Clin Pract 2007;76(2):215-8. Epub 2006 Sep 18.
6. Maji D, Roy RU, Das S, Hoshide S, Numao T, Fukuda T, et al. Prevention of type 2 diabetes in the prediabetic population. J Indian Med Assoc 2005;103(11):609-11.
7. Gubern C, Lopez-Bermejo A, Biarnes J, Vendrell J, Ricart W, Fernández-Real JM. Natural antibiotics and insulin sensitivity: the role of bactericidal/ permeability-increasing protein. Diabetes 2006;55(1):216-24.
8. Biarnes J, Fernandes-Real JM, Fernandez-Castaner M, del Mar García M, Soler J, Ricart W. Differential regulation of insulin action and tumor necrosis factor alpha system activity by metformin. Metabolism 2005;54(2):235-9.
9. Gore DC, Wolf SE, Sanford A, Herndon DN, Wolfe RR. Influence of metformin on glucose intolerance and muscle catabolism following severe burn injury. Ann Surg 2005;241(1):334-42.
10. Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, et al. Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab 2005;288(5):E930-4. Epub 2005 Jan 4.
11. Caballero AE, Delgado A, Aguilar-Salinas CA, Herrera AN, Castillo JL, Cabrera T, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab 2004;89(8):3943-8.
12. Flores-Saenz JL, Trujilo-Arriaga HM, Rivas-Vilchis JF, Mendez-Francisco JD, Alarcon-Aguilar FJ, Roman-Ramos R. Crossover and double blind study with metformin and rosiglitazone in impaired glucose tolerance subjects. Proc West Pharmacol Soc 2003;46:143-7.
13. Morel Y, Golay A, Perneger T, Lehmann T, Vadas L, Pasik C, et al. Metformin treatment leads to an increase in basal, but not insulin-stimulated, glucose disposal in obese patients with impaired glucose tolerance. Diabet Med1999;16(8):650-5.
14. Scheen AJ, Letiexhe MR, Lefebvre PJ. Short administration of metformin improves insulin sensitivity in android obese subjects with impaired glucose tolerance. Diabet Med 1995;12(11):985-9.
15. Widen EI, Eriksson JG, Groop LC. Metformin normalizes nonoxidative glucose metabolism in insulin-resistant normoglycemic first-degree relatives of patients with NIDDM. Diabetes 1992;41(3):354-8.
16. Linday LA. Trivalent chromium and the diabetes prevention program [review]. Med Hypotheses 1997;49(1):47-9.
17. Fujimoto WY, Jablonski KA, Bray GA, Kriska A, Barrett-Connor E, Haffner S, et al. Body size and shape changes and the risk of diabetes in the Diabetes Prevention Program. Diabetes 2007;56(6):1680-5. Epub 2007 Mar 15.
18. Florez JC, Jablonski KA, Kahn SE, Franks PW, Dabelea D, Hamman RF, et al. Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes 2007;56(2):531-6.
19. Relationship of body size and shape to the development of diabetes in the diabetes prevention program. Obesity (Silver Spring) 2006;14(11):2107-17.
20. Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, et al. Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 2005;28(4):888-94.
21. Zinman B, Harris SB, Gerstein HC, Young TK, Raboud JM, Neuman J, et al. Preventing type 2 diabetes using combination therapy: design and methods of the Canadian Normoglycaemia Outcomes Evaluation (CANOE) trial. Diabetes Obes Metab 2006;8(5):531-7.
22. Li CL, Pan CY, Lu JM, Zhu Y, Wang JH, Deng XX, et al. Effect of metformin on patients with impaired glucose tolerance. Diabet Med 1999;16(6):477-81.
23. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 2006;48(2):289-97. Epub 2006 Jan 4.
24. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.